Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA5 | O75582 | 13/20 | 0.53 |
| ▸ | AKT1 | P31749 | 11/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 10/20 | 0.46 |
| ▸ | RPS6KA1 | Q15418 | 9/20 | 0.46 |
| ▸ | AKT2 | P31751 | 3/20 | 0.45 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4717856 | 0.80 | RPS6KA5 (0.65) | RPS6KA5AKT1ROCK1RPS6KA1AKT2 | |
| SCHEMBL690731 | 0.78 | RPS6KA5 (0.63) | RPS6KA5AKT1ROCK1RPS6KA1 | |
| SCHEMBL4720745 | 0.70 | RPS6KA5 (1.00) | RPS6KA5AKT1ROCK1RPS6KA1AKT2 | |
| SCHEMBL14252512 | 0.70 | RPS6KA5 (0.50) | RPS6KA5AKT1ROCK1RPS6KA1AKT2 | |
| SCHEMBL4717195 | 0.69 | RPS6KA5 (0.56) | RPS6KA5AKT1ROCK1RPS6KA1 | |
| SCHEMBL4073188 | 0.69 | RPS6KA5 (0.66) | RPS6KA5AKT1ROCK1RPS6KA1 | |
| SCHEMBL690780 | 0.68 | RPS6KA5 (0.61) | RPS6KA5AKT1ROCK1RPS6KA1AKT2 | |
| SCHEMBL17595570 | 0.67 | RPS6KA5 (0.71) | RPS6KA5AKT1ROCK1RPS6KA1AKT2 | |
| SCHEMBL14534949 | 0.66 | RPS6KA5 (0.61) | RPS6KA5AKT1ROCK1RPS6KA1AKT2 | |
| SCHEMBL4243398 | 0.65 | RPS6KA5 (0.53) | RPS6KA5AKT1ROCK1RPS6KA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490367-B1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-7348339-B2 | 2-(4-amino-furazan-3-yl)-1-ethyl-N-[(2R)-2-morpholinylmethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide; Mitogen- and Stress-Activated Protein (MSK) and Rho (guanosine triphosphate) 1 or 2 kinase inhibitor; neurodegenerative diaeases; antiinflammatory, anticarcinogenic, antiviral and antibacterial agent | GLAXO GROUP LIMITED (GB) | 2008-03-25 | — | — | US | disclosed |
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-09-08 | — | — | US | disclosed |
| EP-1490367-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003080610-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | NR4A3, XDH, MAPK8 | RPS6KA5 375/4885AKT1 598/4885ROCK1 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.